Navigation Links
Anavex advances drug candidate for treatment of Alzheimer's disease
Date:11/28/2007

Results from animal model testing demonstrate ANAVEX 1-41 has significant

neuroprotective and anti-amnesic benefits

GENEVA, Nov. 28 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce promising developments with ANAVEX 1-41, the company's lead drug candidate for Alzheimer's disease. In recent pre-clinical animal studies, ANAVEX 1-41 prevented oxidative stress, which damages and destroys cells and is believed to be a primary cause of Alzheimer's disease. ANAVEX 1-41 also prevented the expression of caspase-3, an enzyme that plays a key role in programmed cell death and in the loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory.

The results are further highlighted in that this activity involves both muscarinic and sigma-1 receptor systems indicating a novel mechanism of action. Published results were presented at the Neuroscience 2007 conference in San Diego, California, and are available at http://www.anavex.com/publications.html. Testing on ANAVEX 1-41 is being conducted in cooperation with Universite Montpellier in France.

"The fact that we have evidence of neuroprotective action, which is essentially protection to any part of the body's nervous system, through the prevention of oxidative stress is a major milestone in the development of ANAVEX 1-41," said Dr. Vamvakides, Chief Scientific Officer of ANAVEX. "With this novel mechanism of action we anticipate that ANAVEX 1-41 may slow the progression of Alzheimer's disease and considerably improve the quality of life of those impacted by the disease as well as their caregivers."

The pre-clinical studies tested ANAVEX 1-41's ability to protect neurons, the nerve cells that make up the central nervous system, from degeneration or death. Testing was conducted in a non-transgenic mouse model of Alzheimer's dis
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
2. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
3. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
4. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
5. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
8. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
9. BioSpace Draws Over 600 Candidates to San Diego Life Science Career Fair
10. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 ... nation’s leading specialty pharmacies, has an expanded team ... clinical pharmacy consultants for prescriber offices in their ... , “We have a variety of Regional ... example, those specializing in hepatitis C help prescribers ...
(Date:12/19/2014)... 18, 2014 iLab Solutions, the global ... of Siri Bryant as the new Director of Institutional ... Core Implementations. These two new leadership positions were created ... by ensuring that iLab continues to meet the needs ... four years, iLab has been deployed at over 450 ...
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is pleased ... elected Chairman of the Board, to succeed Donald Fresne ... but will continue as a member of the Board.  In ... added to the company over almost twenty years, the Board ... Board of Directors has established a Search Committee to find ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... BEIJING, April 9 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:, SVA ... Company,s unaudited financial results for the three and twelve month,periods ended December ... -- Record full year 2008 sales increasing 39% year-over-year ... -- Sold 6.93 million doses of Healive(R) in 2008, up from 5.12 ...
... it,s advanced nutritional supplement, Caplex, to cancer ... pending formulation created by an Oncologist and ... a comprehensive source of the most effective anti-tumor ... from medical research. Impressive changes in the growth ...
... guide designed to help consulting engineers and ... environmentsBUFFALO GROVE, Ill., April 8 Siemens ... Life Science Solutions Design Guide written expressly ... are looking to design and specify effective ...
Cached Biology Technology:Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 2Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 4Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 5Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 6Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 7Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 8Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 9Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 10Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 11Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 12Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 13Cancer Fighting Nutrition Supplement, Caplex, Offers Cancer Patients A New All-Natural Treatment Option 2Siemens Offers Life Science Solutions Design Guide for Consulting Engineers 2
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... crop plant with resistance to the severe maize streak ... has been developed by scientists from the University of ... seed company. The research, published in Plant Biotechnology Journal ... will play an important role in alleviating Africas food ...
... the first four-legged animals sprouted fingers and toes, they took ... say University of Florida scientists writing in Wednesdays issue of ... which have existed for more than half a billion years ... not to eat them, but to grow them. ...
... WASHINGTON, DC August 13, 2007 Young adults who ... degeneration when they grow older, new animal research suggests. ... after methamphetamine discontinuation may be relevant to human methamphetamine ... Institute for Drug Abuse. It suggests that even though ...
Cached Biology News:Conquest of land began in shark genome 2Conquest of land began in shark genome 3Meth exposure in young adults leads to long-term behavioral consequences 2
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... Rabbit polyclonal to Taura Syndrome ... for all tested applications). ... Synthetic peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN ... corresponding to N terminal amino ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Biology Products: